Teva Pharmaceuticals Files 8-K on Financials
Ticker: TEVJF · Form: 8-K · Filed: Jan 29, 2025 · CIK: 818686
| Field | Detail |
|---|---|
| Company | Teva Pharmaceutical Industries Ltd (TEVJF) |
| Form Type | 8-K |
| Filed Date | Jan 29, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-reporting, sec-filing
Related Tickers: TEVA
TL;DR
Teva filed an 8-K on Jan 29, 2025, updating on financials. No major news yet.
AI Summary
On January 29, 2025, TEVA PHARMACEUTICAL INDUSTRIES LTD filed an 8-K report. The filing pertains to the company's results of operations and financial condition, as well as financial statements and exhibits. No specific financial figures or significant events were detailed in the provided excerpt.
Why It Matters
This filing indicates Teva Pharmaceuticals is providing updates on its financial performance and condition to the SEC, which is important for investors to monitor.
Risk Assessment
Risk Level: low — The filing is a routine disclosure of financial information and does not appear to contain any immediate negative news or significant changes.
Key Players & Entities
- TEVA PHARMACEUTICAL INDUSTRIES LTD (company) — Registrant
- January 29, 2025 (date) — Date of Report
FAQ
What specific financial information is being reported in this 8-K filing?
The provided excerpt indicates the filing relates to 'Results of Operations and Financial Condition' and 'Financial Statements and Exhibits', but does not detail specific financial figures.
What is the significance of an 8-K filing?
An 8-K filing is a report of unscheduled material events or corporate changes that are of importance to shareholders and the SEC.
When was this 8-K report filed?
The report was filed on January 29, 2025.
What is Teva Pharmaceutical Industries Ltd's principal executive office address?
The principal executive offices are located at 124 Dvora Hanevi’a Street, Tel Aviv 6944020, Israel.
What is Teva's standard industrial classification code?
Teva's standard industrial classification code is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 533 words · 2 min read · ~2 pages · Grade level 13.1 · Accepted 2025-01-29 07:00:16
Filing Documents
- f8k_012925.htm (8-K) — 15KB
- exh_991.htm (EX-99.1) — 576KB
- 0001171843-25-000493.txt ( ) — 828KB
- gnw-20190101.xsd (EX-101.SCH) — 3KB
- gnw-20190101_def.xml (EX-101.DEF) — 25KB
- gnw-20190101_lab.xml (EX-101.LAB) — 33KB
- gnw-20190101_pre.xml (EX-101.PRE) — 22KB
- f8k_012925_htm.xml (XML) — 3KB
02. Results of Operations and Financial Condition
Item 2.02. Results of Operations and Financial Condition. On January 29, 2025, Teva Pharmaceutical Industries Ltd. issued a press release announcing its financial results for the period ended December 31, 2024. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and the information contained therein is incorporated herein by reference. The information included in this Item 2.02 is being furnished to the Securities and Exchange Commission and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description of Document 99.1 Teva Reports 2024 Full Year and Fourth Quarter Financial Results 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. TEVA PHARMACEUTICAL INDUSTRIES LIMITED Date: January 29, 2025 By: /s/ Eli Kalif Eli Kalif Executive Vice President, Chief Financial Officer